Zotiraciclib

CAS No.

1204918-72-8

MDL No.

MFCD22124499

C₂₃H₂₄N₄O

372.50

InChI Key

VXBAJLGYBMTJCY-NSCUHMNNSA-N

Pack Size	Purity	Price	Availability
1 mg	98+%	$32	In Stock
5 mg	98+%	$37	In Stock
10 mg	98+%	$60	In Stock
25 mg	98+%	$117	In Stock
100 mg	98+%	$334	In Stock
Custom synthesis and bulk supply options are available upon request.

Pack Size

Purity

Price

Availability

Action

1 mg

98+%

$32

In Stock

5 mg

98+%

$37

In Stock

10 mg

98+%

$60

In Stock

25 mg

98+%

$117

In Stock

100 mg

98+%

$334

In Stock

Custom synthesis and bulk supply options are available upon request.

Product Information

CAS No.	1204918-72-8
Product Name	Zotiraciclib

Biological Targets

CDK1·CDK2·CDK7·CDK9·JAK2·

Associated Conditions

hepatocellular carcinoma·hematopoietic and lymphoid system neoplasm·neoplasm·chronic lymphocytic leukemia·gliosarcoma·

* The information provided here is compiled from public sources and is for reference only.

Pricing & Availability

Product Information

Biological Profile

Properties

Biological Targets

Associated Conditions

Documentation

Zotiraciclib

Pricing & Availability

Product Information

Biological Profile

Properties

Biological Targets

Associated Conditions

Related Articles

Efficacy of RNA polymerase II inhibitors in targeting dormant leukaemia cells.

Structure-based design of nitrogen-linked macrocyclic kinase inhibitors leading to the clinical candidate SB1317/TG02, a potent inhibitor of cyclin dependant kinases (CDKs), Janus kinase 2 (JAK2), and Fms-like tyrosine kinase-3 (FLT3).

The multi-kinase inhibitor TG02 overcomes signalling activation by survival factors to deplete MCL1 and XIAP and induce cell death in primary acute myeloid leukaemia cells.

Documentation

Similar Products

TG-02 citrate